Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors (Q54607194)

From Wikidata

Jump to navigation Jump to search

scientific article published on March 4, 2011

Language	Label	Description	Also known as
English	Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors	scientific article published on March 4, 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21378200

Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors (English)

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

1 reference

based on heuristic

inferred from title

Martijn P Lolkema

4

object named as

M. P. Lolkema

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21378200

26 November 2024

Henk M W Verheul

5

object named as

H. M W. Verheul

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21378200

26 November 2024

author name string

M. H G. Langenberg

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21378200

26 November 2024

P. O. Witteveen

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21378200

26 November 2024

J. Roodhart

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21378200

26 November 2024

M. Mergui-Roelvink

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21378200

26 November 2024

E. Brendel

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21378200

26 November 2024

J. Krätzschmar

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21378200

26 November 2024

B. Loembé

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21378200

26 November 2024

A. Nol-Boekel

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21378200

26 November 2024

O. Christensen

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21378200

26 November 2024

J. H M. Schellens

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21378200

26 November 2024

E. E. Voest

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21378200

26 November 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21378200

26 November 2024

publication date

4 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21378200

full work available at URL

http://www.annalsofoncology.org/article/S0923753419376987/pdf

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21378200

26 November 2024

https://api.elsevier.com/content/article/PII:S0923753419376987?httpAccept=text/xml

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

https://api.elsevier.com/content/article/PII:S0923753419376987?httpAccept=text/plain

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

http://academic.oup.com/annonc/article-pdf/22/11/2508/523588/mdq767.pdf

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21378200

22

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21378200

11

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21378200

2508-2515

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21378200

Tumor angiogenesis: therapeutic implications

1

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Antiangiogenic therapy for cancer: current and emerging concepts

2

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

3

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

VEGF inhibition: insights from preclinical and clinical studies

4

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

5

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

6

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

7

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

8

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

9

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Sorafenib in advanced clear-cell renal-cell carcinoma

10

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Sorafenib in advanced hepatocellular carcinoma

11

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours

12

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor

13

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.

14

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review

16

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.

17

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

18

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

19

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Modes of resistance to anti-angiogenic therapy

20

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Pathways mediating resistance to vascular endothelial growth factor-targeted therapy

21

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

The biology of VEGF and its receptors

22

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Platelet: transporter of vascular endothelial growth factor

23

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Platelets Take Up the Monoclonal Antibody Bevacizumab

24

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

25

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

26

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity

27

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

28

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

A phase I study of sunitinib plus bevacizumab in advanced solid tumors

29

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

30

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data

31

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

32

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood

33

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway

34

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Mechanisms of hypertension associated with BAY 43-9006.

35

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition

36

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

37

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

38

1 reference

10.1093/ANNONC/MDQ767

https://api.crossref.org/works/10.1093/ANNONC/MDQ767

26 November 2024

Identifiers

10.1093/ANNONC/MDQ767

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21378200

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21378200

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54607194&oldid=2279966637"